Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice-Reference-Cited by-同舟云学术

Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice

Published:2021-05 Issue: Volume:149 Page:222-232
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tjulandin Sergey,Demidov Lev,Moiseyenko Vladimir,Protsenko Svetlana^ORCID,Semiglazova Tatiana,Odintsova Svetlana,Zukov Ruslan,Lazarev Sergey,Makarova Yuliya,Nechaeva Marina,Sakaeva Dina,Andreev Aleksey,Tarasova Anna,Fadeyeva Natalya,Shustova Mariia,Kuryshev Ivan

Funder

Johnson Space Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

3. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006);Schachter;Lancet,2017

4. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2017

5. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phage display for discovery of anticancer antibodies;New Biotechnology;2024-11

2. A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT);Frontiers in Oncology;2024-09-04

3. Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis;Neurosurgical Review;2024-08-14

4. Interim results of neoadjuvant immunotherapy with prolgolimab in patients with locally advanced MSI / dMMR colorectal cancer;Malignant tumours;2024-07-21

5. Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review;Frontiers in Oncology;2024-07-16